Preclinical studies, such as those using ribociclib in combination with dexamethasone, have shown that CDK4/6 inhibitors, including palbociclib, effectively inhibit the proliferation of B-ALL cell lines (including dexamethasone-resistant cell lines SEM and RCH-ACV) and patient-derived primary cells, inducing G1 phase arrest [51]. This evidence concerns the gene CDK4 and acute lymphoblastic leukemia.